CVKD

Cadrenal Therapeutics, Inc. (CVKD) - Q2 2026 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended June 30, 2026. Cadrenal Therapeutics, Inc. is a late-stage biopharmaceutical company focused on critical care cardiology and orphan cardiovascular conditions. The company operates as a single segment and is classified as a non-accelerated filer, smaller reporting company, and emerging growth company. As of August 13, 2026, there were 3,567,592 shares of common stock outstanding.

Key Financial Metrics

Material Changes vs. Prior Period

• Expense Reduction: Total operating expenses decreased by 24% ($1.8 million) compared to the prior year period. R&D expenses dropped 46% primarily due to reduced Chemistry, Manufacturing, and Controls (CMC) costs and clinical trial preparation costs. G&A expenses decreased 11% due to lower public company costs and franchise taxes, partially offset by severance costs for the former CFO.
• Financing Activity: The company raised significant capital through equity-related activities. In April 2026, a warrant inducement generated approximately $2.6 million in gross proceeds. In June 2026, a PIPE transaction was agreed upon (closing July 1, 2026) for approximately $3.0 million in gross proceeds. Additionally, $1.46 million was raised via the At-The-Market (ATM) facility.
• Asset Acquisitions: The company acquired assets from eXIthera Pharmaceuticals (frunexian) and Veralox Therapeutics (CAD-1005) in late 2025. These were accounted for as asset acquisitions with costs expensed as R&D due to lack of alternative future use at the time of acquisition.

Outlook, Risks, and Management Commentary

• Going Concern Uncertainty: Management has raised substantial doubt about the company's ability to continue as a going concern for at least one year. The company does not have sufficient cash to fund independent Phase 3 clinical trials for its lead candidates (CAD-1005, tecarfarin, frunexian).
• Strategic Pivot: The company has shifted strategy from independent late-stage development to a model focused on strategic out-licensing, co-development partnerships, and portfolio monetization to secure funding.
• Liquidity Runway: As of early August 2026, with cash of approximately $4.2 million (including PIPE proceeds), management believes operations can be funded through the first quarter of 2027. However, this is insufficient to advance product candidates to clinical trial readiness without additional financing.
• Nasdaq Listing Risk: The company previously fell below the $2.5 million stockholders' equity requirement but regained compliance via the April 2026 warrant inducement. A new Nasdaq rule requiring a $5 million Market Value of Listed Securities (MVLS) was stayed as of July 29, 2026, but remains a potential risk if implemented.
• Pipeline Status: CAD-1005 received FDA guidance for a Phase 3 trial but funding is lacking. Tecarfarin received a Rare Pediatric Disease Designation (RPDD) application submission for Kawasaki Disease in July 2026.

Investor Verification Checklist

• Capital Sufficiency: Verify the company's ability to secure the necessary partnerships or financing to fund operations beyond Q1 2027.
• PIPE Transaction Closing: Confirm the full receipt of the ~$3.0 million PIPE proceeds and the status of the stockholder approval required for Series C-1 Warrants.
• Nasdaq Compliance: Monitor the status of the stayed $5 million MVLS rule and the company's stock price to ensure continued listing compliance.
• Strategic Partnerships: Track progress on out-licensing or co-development deals for the Cardiac Acute Critical Care (CACC) Franchise, as independent development is no longer the primary plan.
• Warrant Dilution: Assess the impact of the significant number of outstanding warrants (over 4.5 million) on future dilution if exercised.